retatrutide fda approval status october 2025 Timeline: Week-by-Week Results (48 Weeks) 🎥 Eli Lilly’s next generation

A second-generation GLP-1 RA (semaglutide) was introduced for oral administration as the world firsts large peptide in a tablet (Aroda et al., 2019)

Board certified internal medicine and obesity medicine

Research has demonstrated that individuals with higher body mass indexes (BMI) face increased risk for: Lower-extremity lymphedema Venous disease Phlebolymphedema Delayed wound healing Cellulitis Mobility limitations For this reason, weight management has long been considered an important component of comprehensive lymphedema care

For patients managing both weight or metabolic health and ulcerative colitis, understanding the intersection of these conditions is essential